Welcome to our dedicated page for Quoin Pharmaceuticals news (Ticker: QNRX), a resource for investors and traders seeking the latest updates and insights on Quoin Pharmaceuticals stock.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, with a primary emphasis on severe genetic skin disorders and related conditions. The QNRX news feed on Stock Titan aggregates company press releases and market-moving updates that shed light on the progress of its clinical pipeline, regulatory interactions and financing activities.
Investors following QNRX news can see detailed updates on the development of the company’s lead asset, QRX003, a topical lotion in late-stage pivotal trials for Netherton Syndrome. Quoin regularly reports clinical data from investigator-led pediatric studies and pivotal programs, describing changes in skin condition, pruritus, sleep disturbance and use of concomitant medications in Netherton Syndrome patients. News items also cover initial positive data in Peeling Skin Syndrome and the potential versatility of QRX003 across multiple rare skin diseases.
Regulatory and designation milestones are another key component of Quoin’s news flow. The company has announced Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency for QRX003 in Netherton Syndrome, as well as Rare Pediatric Disease Designation in the United States. These updates provide context on potential market exclusivity and incentives that may affect the long-term outlook for the program.
Quoin’s news also highlights broader corporate developments, including private placement financings with healthcare-focused institutional investors, adoption of equity incentive plans, leadership changes such as the appointment of a new chief financial officer and shareholder meeting outcomes. In addition, the company issues regular communications about its NETHERTON NOW awareness campaign, releasing video episodes that feature patients, advocates and experts discussing the burden of Netherton Syndrome. For readers tracking QNRX, this news stream offers an ongoing view into clinical progress, regulatory events, capital formation and patient advocacy efforts related to Quoin’s rare disease focus.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced a partnership with Queensland University of Technology for an exclusive option on a bi-functional protein targeting Netherton Syndrome. The agreement entails funding a pre-clinical program, with an option for an exclusive global license upon completion. No upfront fees are required, but royalties will apply upon product approval. CEO Dr. Michael Myers emphasized that this complements their lead asset, QRX003, further solidifying their commitment to developing treatments for rare diseases.
Quoin Pharmaceuticals Completes Merger
On October 28, 2021, Quoin Pharmaceuticals (NASDAQ: QNRX) announced the successful closing of its merger with Cellect Biotechnology. The merger resulted in Quoin's rebranding and its shares will trade under the symbol QNRX starting October 29, 2021. Quoin secured $21.5 million in gross proceeds from a private placement financing led by Altium Capital, supplementing a previous $5 million investment. The company aims to advance its product pipeline addressing rare diseases, while shareholders retained a significant portion of equity in the merged entity.